Companies out of the pain business, NOT a hotbed of innovation, NOT COVERED by insurers

.

.

.

Bloomberg news published this analysis below that explains much of the dead end in pain medication:

• companies got out of the pain business.
• there is no hope in sight for effective analgesics
• insurers refuse coverage for more and more pain medications
• insurers refuse coverage for modalities except opioids

.

What kind of medical system:

• forces patients to seek street drugs for pain relief because they are cheaper?
• fails to treat addicts?
• fails to allow cannabis (medical marijuana) one of the safest drugs ever discovered for pain and symptom management?

.

The whole field is a sham ruled by politicians through CDC fiat and the justice department, subject to radical changes:

•  a threat to your care
• a threat to the field of pain management
• a brick wall to any professional contemplating entering the field
  • pain management is complex & time consuming
  • most chronic pain patients have 3 or more pains
  • each pain requires assessment
  • risks patient addiction and/or suicide
  • risks loss of license
• constant change
  • prior authorizations from insurers refused on appeal
  • disability refused for disabling pain
  • onerous computerized opioid database that is not nationwide, not fully completed by pharmacists
  • threats from patients, addicts, DEA, attorney general
  • highly politicized
  • good specialists thrown in jail despite expert testimony of foremost pain specialists – after testimony of addicts who reduced their sentence with lies
  • poor coverage of modalities if any for P.T., acupuncture, massage, integrative pain management, psychology, biofeedback, psychiatry, cannabis, compounded medications

..

Here’s the article, click title to read in full.

.

Tangled Incentives Push Drugmakers Away From an Opioid Solution

.

.

For the drug industry, building a better pain pill is a problem.

.

Pharmaceutical companies have introduced new medicines to treat dependence, reverse overdoses, and deal with opioids’ side effects. But few effective and economically viable alternatives to addictive painkillers have emerged from the laboratory.

.

That’s because of broken incentives, according to economists and industry experts. The payment policies of insurers and government health programs, along with pressure from investors, have encouraged drugmakers to treat the symptoms of the opioid epidemic but discouraged innovations that might get to the root of the problem.

.

New therapies for pain have generally been too expensive, too cumbersome to use, or targeted at too small a group of patients….

 

.

.

.

Different Incentives

.

The incentives to develop a better pain pill differ sharply from those in other areas of research, such as Alzheimer’s disease.

..

Drugmakers have spent billions on more than 100 failed medicines for Alzheimer’s, but a breakthrough would potentially reach a large and lucrative population of elderly patients on Medicare. Any new pain drug would be fighting it out with inexpensive, proven rivals in a politically fraught environment.

.

The White House Council of Economic Advisers estimated this week that abuse of opioids cost the economy about $504 billion in 2015, or nearly three percent of that year’s overall economic output in the U.S. Those costs include health-care expenses, spending on criminal justice and first responders, and lost worker productivity.

.

“There’s currently a lot more costs of addiction that are being borne by society in a more diffuse way,” said Kosali Simon, a health economist at Indiana University….

.

.

.

Effort and Expense

.

Most opioids are cheap generic drugs that have been prescribed for decades, making the effort and expense of developing new painkillers hard to justify.

.

“They’re off-patent, they can be produced by companies that aren’t the original inventors,” said Bertha Madras, a professor of psychobiology at Harvard Medical School and a member of President Donald Trump’s opioid commission. “It becomes a much more expensive proposition to develop and get the approval for an opioid.”

.

Drugmakers have instead invested in developing complex medicines for cancer and rare diseases, which can fetch six-figure price tags.

.

“Companies got out of the pain business,” said Pratap Khedkar of ZS Associates, a sales and marketing consultant who studies the pharmaceutical industry. “It’s not the hotbed of innovation.”…..

.

.

..

Wary Payers

.

Drug plans have been reluctant to pay for abuse-resistant pain medicines, which often cost more and can be more difficult to administer. A recent report from The Institute for Clinical and Economic Review, a nonprofit that evaluates the value of prescription drugs, found that abuse-deterrent opioids weren’t cost-effective for insurers.

.

At the same time, payers are limiting patients’ access to older pain drugs. Cigna Corp.took OxyContin off its list of preferred drugs for 2018, though it still covers other opioids. CVS Health Corp. said its pharmacy-benefits management arm will limit prescriptions to a seven-day supply, and Express Scripts Holding Co. also said it wouldcurb prescriptions.

.

That leaves patients with a difficult choice. Abuse-deterrent painkillers might cost as much as $250 out of pocket. But generic opioids cost as little as $2, according to Denis Patterson, a pain specialist in Reno, Nevada.

.

Abuse-resistant drugs get “denied 90 percent of the time. But the pain pills will get approved every single time,” said Patterson.

.

“Shouldn’t it be flipped,” he said, “in that the things which can get people better should have better coverage?”…..

..

.

.

.

.

.

.

.

.

.

The material on this site is for informational purposes only.

.

It is not legal for me to provide medical advice without an examination.

.

It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

~~

Comments are welcome.

This site is not for email, not for medical questions, and not for appointments.

~~~~~

For My Home Page, click here:  Welcome to my Weblog on Pain Management!

.

Please IGNORE THE ADS BELOW. They are not from me.

.

.

.

.

.

..

..

.

.

.

.

.

.

.

.

..

..

.

.